ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Tennessee » Pulmonary Disease

Top Pulmonary Disease Prescribers in Tennessee

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ELIE MANSOUR M.D.

Pulmonary Disease

25,967

$1.42M

564
390 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

17%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 58%

$55
Average prescription price

Avg: $167

KUMAR YOGESH M.D.

Pulmonary Disease

16,023

$983K

592
436 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 58%

$61
Average prescription price

Avg: $167

ERNESTO MEJIA MD

Pulmonary Disease

15,041

$3.11M

1269
817 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 58%

$207
Average prescription price

Avg: $167

AHMAD IBRAHIMBACHA M,D.

Pulmonary Disease

7,898

$1.22M

737
456 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 58%

$154
Average prescription price

Avg: $167

MICHAEL DIMEO MD

Pulmonary Disease

6,775

$1.17M

699
534 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 58%

$173
Average prescription price

Avg: $167

SURESH ENJETI MD

Pulmonary Disease

5,478

$1.51M

622
480 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 58%

$276
Average prescription price

Avg: $167

DAVID JARVIS MD

Pulmonary Disease

5,383

$406K

416
338 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 58%

$75
Average prescription price

Avg: $167

JOHN JAGGERS M.D.

Pulmonary Disease

5,277

$903K

504
351 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 58%

$171
Average prescription price

Avg: $167

JOY BURBECK M.D.

Pulmonary Disease

4,783

$758K

542
424 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 58%

$159
Average prescription price

Avg: $167

YUNE-GILL JEONG MD

Pulmonary Disease

4,198

$734K

465
397 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 58%

$175
Average prescription price

Avg: $167

RICHARD HUGHES M.D.

Pulmonary Disease

4,189

$778K

522
373 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 58%

$186
Average prescription price

Avg: $167

ROBERT MARCUM M.D.

Pulmonary Disease

4,119

$627K

411
291 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 58%

$152
Average prescription price

Avg: $167

PAUL TALLEY M.D.

Pulmonary Disease

3,792

$137K

220
103 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

15%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 58%

$36
Average prescription price

Avg: $167

M. HUMAYUN KABIR MD

Pulmonary Disease

3,700

$297K

230
128 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 58%

$80
Average prescription price

Avg: $167

WILLIAM FAITH M.D.

Pulmonary Disease

3,207

$431K

452
321 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 58%

$134
Average prescription price

Avg: $167

DOUGLAS KANE M.D.

Pulmonary Disease

3,079

$305K

563
425 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 58%

$99
Average prescription price

Avg: $167

RANDY SUSSMANE-STUBBS MD

Pulmonary Disease

3,077

$151K

542
263 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

30%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 58%

$49
Average prescription price

Avg: $167

MICHAEL WILONS M.D.

Pulmonary Disease

3,075

$462K

386
307 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 58%

$150
Average prescription price

Avg: $167

JATIN KADAKIA MD

Pulmonary Disease

3,053

$539K

348
249 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 58%

$176
Average prescription price

Avg: $167

ASA HEFLIN M.D.

Pulmonary Disease

3,051

$525K

375
292 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 58%

$172
Average prescription price

Avg: $167

IVAN ROBBINS MD

Pulmonary Disease

3,015

$2.18M

165
52 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 58%

$723
Average prescription price

Avg: $167

GARY TREW M.D.

Pulmonary Disease

2,930

$464K

425
368 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 58%

$158
Average prescription price

Avg: $167

VICTOR SALTER MD

Pulmonary Disease

2,912

$857K

283
202 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 58%

$294
Average prescription price

Avg: $167

HASSAN NADROUS M.D.

Pulmonary Disease

2,776

$1.11M

360
178 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 58%

$401
Average prescription price

Avg: $167

MARK PETERS M.D.

Pulmonary Disease

2,706

$656K

289
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 58%

$243
Average prescription price

Avg: $167

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank